Overview

GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
0
Participant gender:
Female
Summary
Purpose:The aim of this project is to prospectively determine whether a single dose of GnRH-agonist administered at the time of implantation increases or not the reproductive outcome in patients undergoing in vitro fertilization ( IVF)/ intracytoplasmatic sperm injection(ICSI) triggered by a GnRH-agonist followed by a small bolus of human chorionic gonadotropin (hCG 1500 IU) the day of oocyte retrieval. Acronyms: GnRH: gonadotropin-releasing hormone FSH: follicle stimulating hormone LH: luteinizing hormone HCG:human chorionic gonadotropin IVF:In vitro fertilization ICSI:intracytoplasmatic sperm injection OHSS:ovarian hyperstimulation syndrome OMEGA: oocyte maturation employing GnRH-agonist OPU: ovum pick up NaCl: sodium chloride
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Centre Hospitalier Universitaire Ibn Rochd
Treatments:
Deslorelin
Pharmaceutical Solutions
Triptorelin Pamoate
Criteria
Inclusion Criteria:

- Female age < 40 years

- Baseline FSH and LH < 12 IU/l.

- Body Mass Index > 18 and < 35 kg/m2

- No uterine (fibroids, mullerian malformations), ovarian ( endometrioma) or adnexa
(hydrosalpinx) abnormalities

- Patients with at least one embryo at transfer time

Exclusion Criteria:

- Very high risk of OHSS (> 30 follicles > 12 mm the day of ovulation triggering).

- Reduced ovarian reserve

- Fertilization failure

- Severe endocrinopathy

- Azoospermia